A new method for preventing tumorigenicity or treating a cancer in a subject includes administering to the subject a Collagen XVII (Col XVII) inhibitor in an amount effective to inhibit and prevent survival, tumorigenesis and metastasis of cancer cells and/or cancer stem cells (CSCs).